Manchester Financial Inc. decreased its holdings in Pfizer Inc. (NYSE:PFE) by 12.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,608 shares of the biopharmaceutical company’s stock after selling 975 shares during the period. Manchester Financial Inc.’s holdings in Pfizer were worth $237,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Heritage Way Advisors LLC lifted its position in Pfizer by 0.6% during the second quarter. Heritage Way Advisors LLC now owns 57,524 shares of the biopharmaceutical company’s stock valued at $2,492,000 after purchasing an additional 354 shares during the last quarter. Natixis bought a new stake in shares of Pfizer in the 2nd quarter worth approximately $258,466,000. Machina Capital S.A.S. lifted its holdings in shares of Pfizer by 14.4% in the 2nd quarter. Machina Capital S.A.S. now owns 43,837 shares of the biopharmaceutical company’s stock worth $1,899,000 after acquiring an additional 5,522 shares during the last quarter. M Holdings Securities Inc. lifted its holdings in shares of Pfizer by 27.9% in the 1st quarter. M Holdings Securities Inc. now owns 39,851 shares of the biopharmaceutical company’s stock worth $1,692,000 after acquiring an additional 8,693 shares during the last quarter. Finally, Integrated Wealth Concepts LLC lifted its holdings in shares of Pfizer by 14.2% in the 2nd quarter. Integrated Wealth Concepts LLC now owns 68,060 shares of the biopharmaceutical company’s stock worth $2,840,000 after acquiring an additional 8,445 shares during the last quarter. Hedge funds and other institutional investors own 71.69% of the company’s stock.

Shares of NYSE:PFE traded up $0.27 during midday trading on Wednesday, reaching $35.70. The company’s stock had a trading volume of 2,093,678 shares, compared to its average volume of 24,067,033. The firm has a 50 day moving average of $35.91 and a 200-day moving average of $40.03. The firm has a market capitalization of $198.73 billion, a P/E ratio of 11.90, a PEG ratio of 2.86 and a beta of 0.66. The company has a quick ratio of 1.21, a current ratio of 1.47 and a debt-to-equity ratio of 0.60. Pfizer Inc. has a 12-month low of $33.97 and a 12-month high of $46.47.

Pfizer (NYSE:PFE) last released its earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.75 by $0.05. The firm had revenue of $13.26 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. The company’s revenue was down 1.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.77 EPS. On average, research analysts predict that Pfizer Inc. will post 2.81 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a dividend of $0.36 per share. This represents a $1.44 annualized dividend and a yield of 4.03%. The ex-dividend date is Thursday, November 7th. Pfizer’s dividend payout ratio (DPR) is 48.00%.

A number of equities research analysts recently commented on the stock. DZ Bank upgraded shares of Pfizer from a “sell” rating to a “hold” rating and set a $36.00 price target for the company in a report on Wednesday, August 28th. Morgan Stanley lowered their price target on shares of Pfizer from $40.00 to $38.00 and set an “equal weight” rating for the company in a report on Tuesday, August 27th. ValuEngine upgraded shares of Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. Goldman Sachs Group reiterated a “buy” rating and set a $49.00 price target on shares of Pfizer in a report on Monday, June 17th. Finally, JPMorgan Chase & Co. upped their price target on shares of Pfizer from $37.00 to $46.00 and gave the company a “neutral” rating in a report on Thursday, September 19th. They noted that the move was a valuation call. Thirteen research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. Pfizer has an average rating of “Hold” and an average target price of $45.25.

In related news, major shareholder Pfizer Inc bought 50,000 shares of the stock in a transaction on Tuesday, September 17th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $900,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Scott Gottlieb bought 3,000 shares of the stock in a transaction on Friday, August 23rd. The shares were bought at an average price of $34.72 per share, for a total transaction of $104,160.00. Following the purchase, the director now directly owns 3,000 shares in the company, valued at approximately $104,160. The disclosure for this purchase can be found here. Corporate insiders own 0.09% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Read More: Compound Interest

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.